This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090772PMC
http://dx.doi.org/10.1155/2011/584238DOI Listing

Publication Analysis

Top Keywords

diabetic retinopathy
12
intravitreal bevacizumab
8
dme pdr
8
pdr
6
ivb
5
intravitreal
4
bevacizumab avastin
4
diabetic
4
avastin diabetic
4
retinopathy 2010
4

Similar Publications

Background: We aimed to characterize factors associated with the under-studied complication of cognitive decline in aging people with long-duration type 1 diabetes (T1D).

Methods: Joslin "Medalists" (n = 222; T1D ≥ 50 years) underwent cognitive testing. Medalists (n = 52) and age-matched non-diabetic controls (n = 20) underwent neuro- and retinal imaging.

View Article and Find Full Text PDF

Purpose: To compare the amplitudes and implicit times of the oscillatory (OPs) of the full-field electroretinograms (ERGs) to those of the 30 Hz flicker ERGs in differentiating eyes with diabetic retinopathy (DR) from normal eyes.

Study Design: Single-center observational study.

Methods: Full-field ERGs were recorded in 55 patients with Type 2 diabetes mellitus (DM) and 20 normal control subjects.

View Article and Find Full Text PDF

Bayesian deep learning applied to diabetic retinopathy with uncertainty quantification.

Heliyon

January 2025

Information Technology Department, Technical College of Informatics-Akre, Akre University for Applied Sciences, Kurdistan Regain, Iraq.

Deep Learning (DL) has significantly contributed to the field of medical imaging in recent years, leading to advancements in disease diagnosis and treatment. In the case of Diabetic Retinopathy (DR), DL models have shown high efficacy in tasks such as classification, segmentation, detection, and prediction. However, DL model's opacity and complexity lead to errors in decision-making, particularly in complex cases, making it necessary to estimate the model's uncertainty in predictions.

View Article and Find Full Text PDF

Prevalence of chronic kidney disease among Chinese adults with diabetes: a nationwide population-based cross-sectional study.

Lancet Reg Health West Pac

February 2025

Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China.

Background: To date, comprehensive data on the distribution of chronic kidney disease (CKD), the most prevalent comorbidity in diabetes, among Chinese adults with diabetes is lacking. Additionally, research gaps exist in understanding the association between CKD and cardiovascular health (CVH), an integrated indicator of lifestyle and metabolic control, within a nationwide sample of Chinese adults with diabetes.

Methods: A nationally community-based cross-sectional survey was conducted in 2018-2020.

View Article and Find Full Text PDF

Background: Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and are routinely used to treat various other eye conditions. However, anti-vascular endothelial growth factor drugs are expensive relative to current care options, and it is unclear whether this additional cost is justified when the immediate risk of vision loss is lower compared to patients with more aggressive ophthalmological conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!